Molecular Dynamics Simulations of Viral Envelope Proteins: Insights into Host Receptor Binding and Drug Resistance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-05-10

Key Takeaways

• Molecular Dynamics (MD) simulations are crucial for understanding the atomic-level dynamics of viral envelope proteins, enabling the elucidation of host receptor binding mechanisms and the structural basis of drug resistance.
• MD simulations, utilizing force fields like CHARMM and AMBER, and incorporating explicit solvent and lipid bilayer models, provide time-resolved insights into conformational changes of viral glycoproteins such as influenza HA and coronaviruses' spike (S) protein.
• Glycan shielding by N- and O-linked glycans on viral envelope proteins significantly impacts immune evasion and receptor interactions, a phenomenon accurately modeled by MD simulations, as demonstrated in studies of HIV-1 Env and SARS-CoV-2 spike.
• MD simulations are instrumental in identifying drug resistance mechanisms by comparing free energy landscapes of wild-type and mutant proteins, revealing allosteric effects and enabling the discovery of cryptic binding pockets for novel inhibitor design.
• Applications extend to veterinary virology, with MD simulations informing the development of vaccines and antivirals for pathogens like canine coronavirus and white spot syndrome virus, by characterizing fusion protein dynamics and envelope protein interactions.

Introduction

Molecular dynamics (MD) simulations have become an indispensable tool in computational virology for investigating the structural and dynamic properties of viral envelope proteins. These proteins, which include hemagglutinin (HA) in influenza viruses, spike (S) glycoproteins in coronaviruses, and fusion (F) or glycoprotein (G) complexes in paramyxoviruses and rhabdoviruses, mediate the critical steps of host receptor recognition and membrane fusion [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>]. Understanding their conformational behavior at atomic resolution is essential for deciphering host tropism, immune evasion, and the molecular basis of drug resistance [<a href="#ref-3">3</a>, <a href="#ref-4">4</a>]. In veterinary medicine, such insights inform the design of vaccines and antivirals for pathogens of livestock, poultry, companion animals, and wildlife [<a href="#ref-5">5</a>, <a href="#ref-6">6</a>].

MD simulations complement experimental structural biology (e.g., cryo-EM, X-ray crystallography) by providing a time-resolved view of protein motions, from local side-chain fluctuations to large-scale domain rearrangements [<a href="#ref-7">7</a>, <a href="#ref-8">8</a>]. They allow the calculation of free energy landscapes, identification of cryptic binding pockets, and assessment of mutation-induced allosteric effects that may alter receptor affinity or antibody neutralization [<a href="#ref-9">9</a>, <a href="#ref-10">10</a>]. This review examines the theoretical foundations of MD simulations as applied to viral envelope proteins, surveys key findings across viral families relevant to veterinary virology, and discusses implications for understanding drug resistance mechanisms.

Computational Methods in Viral Envelope Protein Simulations

MD simulations rely on classical force fields (e.g., CHARMM, AMBER, OPLS, GROMOS) to model the interatomic interactions of proteins, lipids, and water [<a href="#ref-11">11</a>]. For envelope proteins, accurate representation of the lipid bilayer environment is critical, as many glycoproteins are membrane-anchored and undergo pH- or receptor-dependent conformational transitions [<a href="#ref-2">2</a>, <a href="#ref-12">12</a>]. Simulations of soluble ectodomains are often performed using explicit solvent models (e.g., TIP3P, SPC/E) with periodic boundary conditions and particle mesh Ewald electrostatics [<a href="#ref-13">13</a>, <a href="#ref-14">14</a>]. Typical simulation timescales range from nanoseconds to microseconds for conventional MD, although enhanced sampling techniques such as replica exchange, metadynamics, and Markov state models (MSMs) can access slower conformational changes [<a href="#ref-7">7</a>, <a href="#ref-15">15</a>].

The choice of force field and simulation protocol must account for post-translational modifications, particularly N- and O-linked glycans, which play a major role in shielding epitopes and modulating receptor interactions [<a href="#ref-8">8</a>, <a href="#ref-16">16</a>, <a href="#ref-17">17</a>]. Glycan parameters are often taken from the GLYCAM force field or CHARMM carbohydrate force fields [<a href="#ref-18">18</a>]. Solvation free energies and binding affinities are frequently calculated using end-point methods such as MM/PBSA or MM/GBSA, or more rigorous free energy perturbation (FEP) [<a href="#ref-9">9</a>, <a href="#ref-14">14</a>]. The following table summarizes common computational components used in viral glycoprotein MD studies.

Applications to Influenza Hemagglutinin

Influenza A viruses, including those circulating in avian and swine populations, rely on hemagglutinin (HA) for receptor binding and membrane fusion. MD simulations have been instrumental in characterizing the conformational dynamics of HA and the effects of antigenic drift mutations [<a href="#ref-4">4</a>]. The convergent evolution of mutations such as N156K in A(H1N1)pdm09 HA was shown to contribute to antigenic cluster transitions, with MD studies revealing altered loop dynamics in the receptor binding domain [<a href="#ref-4">4</a>]. Simulations of avian HA variants have helped correlate glycan binding specificity (α2,3 vs α2,6 sialic acids) with host tropism, a key factor for pandemic risk assessment [<a href="#ref-4">4</a>, <a href="#ref-19">19</a>]. Additionally, MD has been used to investigate the M2 proton channel and its resistance to adamantane drugs, although M2 is not an envelope glycoprotein per se; however, the principles of resistance mutation analysis apply broadly [<a href="#ref-19">19</a>].

Coronaviruses: Spike Protein Dynamics and Receptor Interactions

Coronaviruses such as SARS-CoV-2 (zoonotic), MERS-CoV (camelid origin), and canine coronavirus (CCoV) have been extensively studied using MD simulations of their spike (S) proteins [<a href="#ref-5">5</a>, <a href="#ref-7">7</a>, <a href="#ref-20">20</a>, <a href="#ref-21">21</a>]. The prefusion state of S exists in a metastable conformation that transitions to a postfusion state upon receptor engagement and proteolytic cleavage. The D614G mutation, which arose early in the SARS-CoV-2 pandemic, was shown by Kearns et al. using MD to reshape allosteric networks and opening mechanisms, increasing accessibility of the receptor binding domain (RBD) [<a href="#ref-7">7</a>]. Other mutations, such as N481K, have been characterized structurally and functionally to alter RBD dynamics and immune recognition [<a href="#ref-20">20</a>]. Intra-host recombination in SARS-CoV-2 can produce epistatic spike interactions that influence temperature-dependent adaptation [<a href="#ref-21">21</a>].

Glycan shielding is a critical factor in immune evasion; MD simulations have revealed how N-glycans on the SARS-CoV-2 spike modulate tilting and exposure of epitopes, analogous to mechanisms observed in HIV-1 Env [<a href="#ref-8">8</a>, <a href="#ref-17">17</a>]. The Omicron variant epitope reorganization linked to sotrovimab resistance was elucidated through MD and glycan analysis [<a href="#ref-17">17</a>]. Allosteric effects induced by RBD mutations have been mapped using energy landscape analysis and mutational profiling [<a href="#ref-9">9</a>]. MD simulations combined with virtual screening have identified small molecules and natural compounds that disrupt the spike-ACE2 interface, including cannabidiol and cinnamic acid derivatives [<a href="#ref-14">14</a>, <a href="#ref-22">22</a>]. In a veterinary context, a heptad repeat 2 (HR2)-derived peptide inhibitor for canine coronavirus was designed and characterized using MD, providing a basis for fusion inhibitor development [<a href="#ref-5">5</a>].

Flavivirus and Togavirus Envelope Proteins

Dengue virus (DENV) and Zika virus (ZIKV) are mosquito-borne flaviviruses that can infect nonhuman primates and other mammals. MD simulations of the DENV envelope (E) protein have been used to identify inhibitors targeting the prefusion E protein, using a consensus AI-based and physics-based virtual screening approach [<a href="#ref-23">23</a>]. Variations in the E protein of ZIKV, including potential O-glycosylation sites, have been modeled to assess impacts on viral stability and receptor binding [<a href="#ref-24">24</a>]. Tick-borne encephalitis virus (TBEV) E protein has been studied for molecular mimicry that may trigger autoimmunity, with MD providing conformational insight into epitope exposure [<a href="#ref-3">3</a>].

Retrovirus Envelope Glycoproteins: HIV-1 and FIV

HIV-1 Env (gp120-gp41) remains a paradigmatic system for MD studies of viral envelope dynamics. The conformational variability of the Env trimer and its vulnerability to broadly neutralizing antibodies have been mapped using long-timescale simulations [<a href="#ref-1">1</a>]. N-glycans on HIV-1 Env modulate its tilting relative to the membrane, affecting accessibility of conserved epitopes [<a href="#ref-8">8</a>]. The HIV-1 envelope protein, when embedded in a lipid bilayer, exhibits distinct dynamics that can be captured with coarse-grained and all-atom MD [<a href="#ref-2">2</a>]. Compounds such as allophycocyanin have been shown through MD and experimental assays to inhibit HIV-1 gp120 and reverse transcriptase via enthalpy-driven binding [<a href="#ref-25">25</a>]. These findings are relevant to veterinary lentiviruses such as FIV, for which envelope glycoprotein dynamics remain understudied but conceptually analogous.

Rhabdovirus and Filovirus Glycoproteins

Rabies virus (RABV) glycoprotein G mediates receptor binding (neurotropism) and pH-dependent fusion. While fewer MD studies have been published on RABV G, the principles derived from other class III fusion proteins can be applied. Ebola virus (EBOV) glycoprotein (GP) has been targeted by QSAR-guided and fragment-based drug design using MD to evaluate monoterpenoid inhibitors that bind the GP1-GP2 interface [<a href="#ref-26">26</a>]. These approaches can be extended to veterinary filoviruses such as Lloviu virus or other rhabdoviruses.

Envelope Protein Assembly and Viroporin Interactions

MD simulations have also been applied to viral envelope assembly. The SARS-CoV-2 envelope (E) protein, a small viroporin, has been studied for its synergistic protein-protein and protein-lipid interactions that drive assembly with the M protein [<a href="#ref-11">11</a>]. Clustering of M and E proteins in lipid bilayers influences virion morphogenesis [<a href="#ref-12">12</a>]. In white spot syndrome virus (WSSV), a crustacean pathogen, multi-target inhibitors against envelope proteins VP28, VP26, and VP24 have been investigated using MD and virtual screening, demonstrating the applicability of these methods in aquaculture virology [<a href="#ref-6">6</a>].

Identifying Drug Resistance Mechanisms Through MD

Drug resistance mutations often arise in envelope proteins under selective pressure from antivirals or host immune responses. MD simulations can elucidate the structural basis of resistance by comparing free energy landscapes of wild-type and mutant proteins in the presence or absence of inhibitors. For SARS-CoV-2, resistance to monoclonal antibodies like sotrovimab was linked to glycan shielding and epitope reorganization, with MD capturing the altered dynamics of the RBD [<a href="#ref-17">17</a>]. In HIV-1, resistance to entry inhibitors such as maraviroc (targeting CCR5) involves mutations in gp120 that alter coreceptor binding preferences; MD studies have mapped these conformational changes [<a href="#ref-1">1</a>, <a href="#ref-25">25</a>]. For influenza, mutations in HA that reduce binding to neutralizing antibodies are frequently located at antigenic sites and can be predicted by analyzing the flexibility and solvent accessibility of the HA surface [<a href="#ref-4">4</a>, <a href="#ref-19">19</a>].

Cryptic pocket identification is a powerful application of MD. By simulating protein dynamics in the absence of ligand, transient pockets may appear that are not evident in static crystal structures. These pockets can then be targeted by small molecule inhibitors. This strategy has been successfully applied to the SARS-CoV-2 spike RBD and the influenza HA stem region [<a href="#ref-27">27</a>, <a href="#ref-28">28</a>]. Allostery also plays a key role in drug resistance; the D614G mutation in spike was shown to allosterically stabilize the open conformation of the RBD, enhancing ACE2 binding and in some cases affecting inhibitor efficacy [<a href="#ref-7">7</a>].

Conclusion and Future Perspectives

MD simulations of viral envelope proteins have provided profound insights into the atomic-level dynamics that govern host receptor binding and drug resistance. By integrating enhanced sampling techniques, accurate force fields, and experimental validation, computational virologists can predict the effects of mutations, identify cryptic pockets, and guide the rational design of vaccines and antivirals for both human and animal pathogens. Veterinary applications, including canine coronavirus fusion inhibitors, WSSV envelope protein blockers, and influenza HA host range determinants, underscore the translational potential of these methods [<a href="#ref-4">4</a>, <a href="#ref-5">5</a>, <a href="#ref-6">6</a>]. Future directions include the use of machine learning to accelerate free energy calculations, the development of more realistic membrane models, and the application of coarse-grained MD to entire viral particles [<a href="#ref-7">7</a>, <a href="#ref-12">12</a>]. The workflow below illustrates a typical computational pipeline for studying receptor binding and drug resistance in viral envelope proteins.

graph TD
 A["Experimental Structure / Homology Model"] --> B["System Setup: Protein, Glycans, Lipid Bilayer, Solvent, Ions"]
 B --> C["Energy Minimization and Equilibration"]
 C --> D["Production MD Simulation (Conventional or Enhanced Sampling)"]
 D --> E{"Analysis"}
 E --> F["Conformational Dynamics (RMSD, PCA, FEL)"]
 E --> G["Binding Free Energy Calculations (MM/PBSA, FEP)"]
 E --> H["Mutation Effects: Allostery, Stability, Resistance"]
 E --> I["Cryptic Pocket Detection (fpocket, MDpocket)"]
 F --> J["Receptor Binding Mechanism"]
 G --> J
 H --> K["Drug Resistance Prediction"]
 I --> L["Virtual Screening for Novel Inhibitors"]
 L --> M["In Vitro / In Vivo Validation"]

The continued maturation of MD methodology, combined with advances in structural biology and artificial intelligence, promises to further unravel the complex dynamics of viral envelope proteins and accelerate the development of countermeasures against emerging zoonotic and veterinary pathogens.

References

Related Clinical & Scientific Guides

• A Practical Guide to Detecting Antimicrobial Resistance Genes in Shotgun Metagenomic Data
• Computational Immunology: Modeling the Immune System
• How to Set Hard Filters for Germline Variant Calling: A Practical Guide to GATK Best Practices